As observed in our study, elevated ISG15 expression is an independent factor of HER2 expression indicating that targeting ISG15 may be an attractive treatment option for HER2-positive and/or hormone receptor-negative tumour which is accompanied with severe type of BC that has no target therapy yet as they mainly showed resistance to hormonal pathway drugs [50, 51]. The gene discussed is ERBB2; the disease is breast cancer.